AKT1 and non-small cell lung carcinoma: As persistent activation of PI3K/AKT pathway has been documented play a central role in mediating primary and/or acquired resistance of NSCLC harboring EGFR mutation to EGFR-targeted agents [40], the findings in this manuscript thus provide an alternative upstream source.